Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.

[1]  A. Secord,et al.  Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). , 2015, Gynecologic oncology.

[2]  Madison,et al.  Revised surveillance case definition for HIV infection--United States, 2014. , 2014, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  D. Blackhurst,et al.  Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary? , 2013, Gynecologic oncology.

[4]  A. Gabizon,et al.  Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up? , 2010, Anti-cancer drugs.

[5]  K. Odunsi,et al.  High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies , 2010, Chemotherapy.

[6]  S. Montoto,et al.  British HIV Association guidelines for HIV‐associated malignancies 2008 , 2008, HIV medicine.

[7]  M. Markman,et al.  Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. , 2004, Gynecologic oncology.

[8]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Berry,et al.  Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies , 2004, Cancer investigation.

[10]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[11]  U. Hengge,et al.  Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. , 2001, European journal of cancer.

[12]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[16]  S. Stewart,et al.  Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Testa,et al.  AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Redfield,et al.  Lower extremity lymphedema caused by acquired immune deficiency syndrome-related Kaposi's sarcoma: case report and review of the literature. , 1995, Journal of vascular surgery.

[19]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.